Resource Tracking
The HIV
Vaccines and Microbicides Resource Tracking
Working Group Report 2009
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008.
Released in Cape Town at
the IAS conference, this year's report shows
that in 2008, US$868 million was spent on
vaccines, US$244 million on
microbicides, and US$81 million on other new
prevention options such as
pre-exposure prophylaxis using antiretroviral
drugs (PrEP) and the
rollout of medical male circumcision. These
amounts reflect a 10% decline in funding for
vaccines and an 8%
increase in microbicides research funding
between 2007 and 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it is critical that funding for HIV prevention research funding is sustained.
AVAC serves as the secretariat for the HIV Vaccines and Microbicides Resource Tracking Working Group, which also includes the Alliance for Microbicide Development, the International AIDS Vaccine Initiative, and UNAIDS. This new report along with archives of the Working Group's previous reports can be found at www.hivresourcetracking.org.
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it is critical that funding for HIV prevention research funding is sustained.
AVAC serves as the secretariat for the HIV Vaccines and Microbicides Resource Tracking Working Group, which also includes the Alliance for Microbicide Development, the International AIDS Vaccine Initiative, and UNAIDS. This new report along with archives of the Working Group's previous reports can be found at www.hivresourcetracking.org.